Abstract: Dosing regimen for transdermal delivery of hormones comprising a 28 day treatment cycle with a fixed treatment interval and a fixed rest interval.

Abstract: The invention pertains to N-acetylated, N, O-carboxyalkylchitosans and methods for using the chitosans to treat disorders, such as cancer, nervous system disorders, urinary tract disorders, and reproductive tract disorders.

Abstract: Dosing regimen for transdermal delivery of hormones comprising a variable treatment cycle and a variable rest interval.

Abstract: The present invention provides methods and compositions for delivering a therapeutic agent across a membrane that has limited permeability for the therapeutic agent. The method includes delivering the therapeutic agent to the membrane in a composition which includes a sulphated chitinous polymer as a primary carrier.

Abstract: Compositions and methods for modifying biologically active substances to achieve multi-day delivery of such substances, particularly through oral or parenteral administration, are disclosed. The compositions include the biologically active substance conjugated to a carrier having a suitably long half life, typically more than one day, wherein the conjugate optionally contains a spacer linking the carrier to the biologically active substance. Pharmaceutical formulations of the conjugates are also disclosed, as are methods of extending delivery of a single dose of a biologically active substance for more than one day.

Abstract: A method of enclosing an active ingredient layer between a release liner and a backing layer of a dermal patch by ultrasonically welding a seal between the backing layer and the release liner. A pressure sensitive layer is further provided between the backing layer and release liner.

Abstract: This invention relates to a transdermal drug delivery device that comprises an active ingredient (Al) layer, having a skin contacting surface and a non-skin contacting surface and comprising a volatile component, a release liner impermeable to the volatile component adjacent the skin contacting surface of the Al layer having a pe?meter that extends beyond the perimeter of the Al layer in all directions, and an overlay comprising a pressure sensitive adhesive (PSA) that does not absorb the volatile component adjacent the non-skin contacting surface of the Al layer having a pe?meter of which extends beyond the penmeter of the Al layer in all directions, wherein the release liner and the PSA of the overlay are in contact with and adhered to each other around the pe?meter of the Al layer to form a seal that reduces or prevents volatile component loss.

Abstract: Methods of treating a subject suffering from a disorder in a mucosal tissue, such as interstitial cystitis; cancer in a mucous membrane such as bladder or vaginal cancer; Crohn's disease; inflammatory bowel disease or colitis, by administering a medicament containing a sulfated chitinous polymer administered topically are described. Pharmaceutical compositions containing the sulfate chitinous polymer are also disclosed.

Abstract: A transdermal drug delivery device is disclosed. Over an extended wear period, the device causes cumulative moderate irritation plus significant irritation of less than 5% and/or achieves a meaningful degree of detachment over a seven day period of less than 20%.

Abstract: Methods of treating a subject suffering from a disorder in a mucosal tissue, such as interstitial cystitis; cancer in a mucous membrane such as bladder or vaginal cancer; Crohn's disease; inflammatory bowel disease or colitis, by administering a medicament containing a sulfated chitinous polymer administered topically are described. Pharmaceutical compositions containing the sulfate chitinous polymer are also disclosed.

Abstract: Compositions and methods for the treatment of bladder cancer include intravesical dosage forms of a neoplastic agent and a permeation enhancer. The neoplastic agent may be valrubicin. Pharmaceutical compositions include intravesical dosage forms of a neoplastic agent complexed liposomes. Tight junction openers may be used for the effective delivery of the neoplastic agent.

Abstract: The invention pertains to N-acetylated, N, O-carboxyalkylchitosans and methods for using the chitosans to treat disorders, such as cancer, nervous system disorders, urinary tract disorders, and reproductive tract disorders.

Abstract: The invention pertains to N-acetylated, N, O-carboxyalkylchitosans and methods for using the chitosans to treat disorders, such as cancer, nervous system disorders, urinary tract disorders, and reproductive tract disorders.

Abstract: The present invention provides methods and compositions for delivering a therapeutic agent across a membrane that has limited permeability for the therapeutic agent. The method includes delivering the therapeutic agent to the membrane in a composition which includes a sulphated chitinous polymer as a primary carrier.

Abstract: The present invention provides methods and compositions for delivering a therapeutic agent across a membrane that has limited permeability for the therapeutic agent. The method includes delivering the therapeutic agent to the membrane in a composition which includes a sulphated chitinous polymer as a primary carrier.

Abstract: Methods of treating a subject suffering from a disorder in a mucosal tissue, such as interstitial cystitis; cancer in a mucous membrane such as bladder or vaginal cancer; Crohn's disease; inflammatory bowel disease or colitis, by administering a medicament containing a sulfated chitinous polymer administered topically are described. Pharmaceutical compositions containing the sulfate chitinous polymer are also disclosed.

Abstract: The invention pertains to N-acetylated, N, O-carboxyalkylchitosans and methods for using the chitosans to treat disorders, such as cancer, nervous system disorders, urinary tract disorders, and reproductive tract disorders.

Abstract: The present invention relates to drug delivery devices for moist tissue, in particular mucosal tissue and tissue in the serous cavities, as well as a method of its use. The devices, which contain NOCC, are adherent to the mucosal tissue, allowing localized drug delivery. The devices are particularly useful in vaginal, buccal and ocular devices.

Abstract: The present invention provides methods and compositions for delivering a therapeutic agent across a membrane that has limited permeability for the therapeutic agent. The method includes delivering the therapeutic agent to the membrane in a composition which includes a sulphated chitinous polymer as a primary carrier.

Abstract: The invention provides a vessel for biological materials comprising a multilayer polymeric barrier material that has very low permeability to small molecules, such as water and oxygen, high flexibility and softness, and is resistant to tearing. The invention is particularly useful for forming vessels that receive biological fluids, such as ostomy bags and bags for storing blood, blood products, and IV solutions. The vessel comprises a flexible, multilayer, polymeric barrier material comprising (1) a first sandwich polymer layer, (2) at least one sandwiched, oriented liquid crystal polymer layer, and (3) a second sandwich polymer layer, the first and second sandwich layers disposed to sandwich the liquid crystal layer therebetween.